



(51) International Patent Classification:

A61K 40/35 (2025.01) C07K 14/55 (2006.01)
A61P 35/00 (2006.01) C07K 14/705 (2006.01)
A61K 38/20 (2006.01) A61K 38/19 (2006.01)
A61K 40/31 (2025.01) C07K 14/52 (2006.01)

(21) International Application Number:

PCT/US2024/056286

(22) International Filing Date:

15 November 2024 (15.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/600,011 16 November 2023 (16.11.2023) US

(71) Applicant: SENTI BIOSCIENCES, INC. [US/US]; 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).

(72) Inventors: NGUYEN, Aaron Ngocky; c/o SENTI BIOSCIENCES, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). HONG, En-


ping; c/o SENTI BIOSCIENCES, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). KAVERI, Deepika; c/o SENTI BIOSCIENCES, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).

(74) Agent: NEWMAN, Zachary R. et al.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHODS OF ENHANCING ENGINEERED IMMUNE CELL CYTOTOXICITY

FIG. 1



Gene Circuit	Logic Gating: FLT3 OR CD33 NOT EMCN
①	FLT3-targeting scFv; part of bivalent activating CAR (aCAR)
②	CD33-targeting scFv; part of bivalent activating CAR (aCAR)
③	EMCN inhibitory CAR (iCAR)
④	crIL-15 (novel IL-15 molecule)

(57) Abstract: Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*